Atlas Trials

To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma

Clinical trial NCT07454187 · RECRUITING

Trial details

NCT number
NCT07454187
Sponsor
Hangzhou Sumgen Biotech Co., Ltd.
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Relapsed/Refractory Multiple Myeloma
Start date
2026-04-16
Primary completion
2027-09-30
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.